newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

- CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / November 3, 2025 / CASI